Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of bevacizumab timing during neoadjuvant chemoradiation for oesophageal adenocarcinoma
NL-OMON47705Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab in esophageal adenocarcinoma (EAC) (2 arms), sponsored by Vrije University Medical Center. Primary endpoints: Change in tumour VEGF mRNA expression during neoadjuvant chemoradiation, VEGFR phosphorylation in bevacizumab-treated cohort and 1 more. Started Feb 2015; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON47705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47705.